Peter MacCallum Cancer Centre and Affymetrix Initiate Research Collaboration
Microarray technology will initially be used to study ovarian cancer and carcinoma.!--h2>
Affymetrix entered into a five-year collaboration with the Peter MacCallum Cancer Centre in Melbourne, Australia, to analyze genomic information across large patient samples. Under terms of the agreement, Peter Mac researchers will use Affymetrix’ GeneChip® microarray technology for translational research projects, beginning with studies on ovarian cancer and carcinoma of unknown primaries.
The Affymetrix technology will enable them to more rapidly discover RNA and DNA patterns that can better classify, manage, and treat complex diseases.
“We are keen to help our collaborators across Australia gain access to Affymetrix technology, as we continue to develop as a major center for cancer genomics and genetics,” says David Bowtell, Ph.D., director of research at the Peter MacCallum Cancer Centre. “We also see the program providing opportunities to interact with other centers worldwide that are involved in translational research.”